US Patent awarded to HydRIS® vaccine stabilisation device
Nova is proud to announce that our HydRIS® vaccine stabilisation device has been awarded a US patent. HydRIS ® enables pharmaceuticals to be dried and stabilised on to a fibrous membrane, giving long term stability over a wide temperature range (from below 0ºC to > 50º). At the point of use, the content of the syringe is flushed through the HydRIS® device (typically saline or water for injection) and the re-hydrated active is delivered via the needle, in a single action. Nova believes that this technology should significantly improve vaccine availability in the developing world as it eliminates the need for cold chain storage of vaccines.
Downloads
Download all our latest product lists, this months Newsletter and news articles from Nova Laboratories.
Downloads
Career Opportunities
We welcome speculative enquiries and applications from anyone with experience in the pharmaceutical industry, the right attitude and relevant qualifications.
Know More